Published online Feb 16, 2021. doi: 10.12998/wjcc.v9.i5.1005
Peer-review started: September 7, 2020
First decision: December 3, 2020
Revised: December 12, 2020
Accepted: December 22, 2020
Article in press: December 22, 2020
Published online: February 16, 2021
Processing time: 145 Days and 0.3 Hours
Metabolic syndrome (MetS) is related to poor cognitive function. However, the results of previous studies were inconsistent, and whether the ApoEε4 allele modifies the association remains unclear.
To elucidate the relationships among MetS, ApoEε4, and cognitive dysfunction in an elderly population in China.
One hundred elderly patients with MetS and 102 age- and gender-matched controls were included in the study. Baseline clinical characteristics and biochemical index for glucose and lipid metabolism were obtained. The distribution of ApoEε4 was assessed with PCR restriction fragment length polymorphism analysis. Cognitive function was evaluated by mini-mental status examination at the 1-year follow-up examination.
Compared with controls, MetS patients had worse cognitive function and decreased ability to participate in activities of daily life (P = 0.001 and 0.046, respectively). Patients with cognitive dysfunction had higher prevalence of MetS (62.1% vs 36.4%, P < 0.001) and were more likely to carry the ApoEε4 allele (22.3% vs 10.1%, P = 0.019). Multivariate logistic regression analyses showed that diagnosis with MetS, severe insulin resistance, status as an ApoEε4 carrier, higher systolic blood pressure, and larger waist circumference were risk factors for cognitive dysfunction (P < 0.05). Repeated-measures analysis of variance, performed with data collected at the 1-year follow-up, revealed continuous influences of MetS and ApoEε4 on the deterioration of cognitive function (time × team, P < 0.001 for both).
Diagnosis of MetS and ApoEε4 carrier status were persistently associated with cognitive dysfunction among an elderly population in China.
Core Tip: A case-control study was performed to evaluate the association between metabolic syndrome (MetS), ApoEε4, and cognitive dysfunction in an elderly population. With a multivariate analysis, we found that both MetS and status as an ApoEε4 carrier were risk factors for cognitive dysfunction. Moreover, with repeated-measures analysis of variance performed with data collected at the 1-year follow-up, we found continuous influences of MetS and ApoEε4 on the deterioration of cognitive function. These findings suggested that MetS and ApoEε4 carrier status were persistently associated with cognitive dysfunction among an elderly population.